Skip to main content
. 2020 Dec 4;9(12):3939. doi: 10.3390/jcm9123939

Figure 2.

Figure 2

An overview of the suggested therapeutic potential of miRNAs in Myotonic Dystrophy type I (DM1) by targeting downstream targets of MBNL1, upregulating mRNA levels of MBNL1, or downregulating mRNA levels of CELF1 by the use of miRNA mimics or anti-miRs. (A) The use of an miR-1 mimic to circumvent the detrimental effect of MBNL1 sequestration, resulting in a downregulation of downstream targets and symptom alleviation. (B) The use of an anti-miR for miRNA inhibitors of MBNL1 to increase expression levels in DM1 and alleviate symptoms. (C) The use of a miRNA mimic of inhibitors of CELF1 to reduce its expression and alleviate symptoms in DM1. MBNL1 = muscleblind-like 1, CELF1 = CUG-BP and ETR-3-like factors family member 1, CACNA1C = Voltage-dependent L-type calcium channel subunit alpha-1C, GJA1 = connexin 43. Created with BioRender.com.